Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines
Related Experiment Video
Updated: May 5, 2026
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Virgil Schijns1, Eric Tartour2, Jaroslav Michalek3
1Immune Intervention, Cell Biology & Immunology Group, Wageningen University, Wageningen, The Netherlands; Epitopoietic Research Corporation, Namur, Belgium.
Abstract:
Tumor growth is controlled by natural antitumor immune responses alone or by augmented immune reactivity resulting from different forms of immunotherapy, which has demonstrated clinical benefit in numerous studies, although the overall percentage of patients with durable clinical responses remains limited. This is attributed to the heterogeneity of the disease, the inclusion of late-stage patients with no other treatment options and advanced tumor-associated immunosuppression, which may be consolidated by certain types of chemotherapy. Despite variable responsiveness to distinct types of immunotherapy, therapeutic cancer vaccination has shown meaningful efficacy for a variety of cancers. A key step during cancer vaccination involves the appropriate modeling of the functional state of dendritic cells (DCs) capable of co-delivering four critical signals for proper instruction of tumor antigen-specific T cells. However, the education of DCs, either directly in situ, or ex vivo by various complex procedures, lacks standardization. Also, it is questioned whether ex vivo-prepared DC vaccines are superior to in situ-administered adjuvant-guided vaccines, although both approaches have shown success. Evaluation of these variables is further complicated by a lack of consensus in evaluating vaccination clinical study end points. We discuss the role of signals needed for the preparation of classic in situ and modern ex vivo DC vaccines capable of proper reprogramming of antitumor immune responses in patients with cancer.
Insights
Therapeutic cancer vaccination shows promise but faces challenges in patient response. Standardizing dendritic cell (DC) vaccine preparation and evaluation is crucial for improving antitumor immunity and clinical outcomes in cancer patients.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Immunotherapy, including therapeutic cancer vaccination, offers clinical benefits but limited durable responses in cancer patients.
- Challenges include disease heterogeneity, advanced patient stages, and tumor-induced immunosuppression.
- Dendritic cells (DCs) are key for instructing tumor antigen-specific T cells, but their preparation lacks standardization.
Purpose of the Study:
- To discuss the critical signals for preparing dendritic cell (DC) vaccines for cancer immunotherapy.
- To compare in situ and ex vivo DC vaccine approaches for reprogramming antitumor immune responses.
- To highlight the need for standardized methods and endpoint evaluation in DC vaccination studies.
Main Methods:
- Review and discussion of the signals required for effective dendritic cell (DC) vaccine preparation.
- Comparison of in situ versus ex vivo dendritic cell (DC) vaccine administration strategies.
- Analysis of challenges in evaluating clinical endpoints for cancer vaccination studies.
Main Results:
- Dendritic cell (DC) vaccines require precise modeling of four critical signals for optimal T cell instruction.
- Both in situ and ex vivo DC vaccination approaches have demonstrated success, but standardization is lacking.
- Lack of consensus in evaluating clinical endpoints complicates the assessment of vaccination efficacy.
Conclusions:
- Standardizing the preparation and evaluation of dendritic cell (DC) vaccines is essential for enhancing antitumor immune responses.
- Further research is needed to optimize DC vaccine strategies for improved clinical outcomes in cancer patients.
- Addressing heterogeneity and immunosuppression is critical for maximizing the efficacy of cancer immunotherapies.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:21Vaccines
01:51Vaccinations
01:40Cell-mediated Immune Responses
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...